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Research, The Queen Elizabeth Hospital, Adelaide, Australia, 3) Therapeutics Research Centre, School of Medicine, University of Queensland, 4) Royal Brisbane
and Women’s Hospital, 5) Burns, Trauma and Critical Care Research Centre, University of Queensland, Herston, Brisbane, Queensland, Australia and 6) Institute
of Translational Medicine, University of Liverpool, Liverpool, UKAbstractTreatment of infectious diseases is becoming increasingly challenging with the emergence of less-susceptible organisms that are poorly
responsive to existing antibiotic therapies, and the unpredictable pharmacokinetic alterations arising from complex pathophysiologic
changes in some patient populations. In view of this fact, there has been a progressive work on novel dose optimization strategies to
renew the utility of forgotten old antibiotics and to improve the efﬁcacy of those currently in use. This review summarizes the different
approaches of optimization of antibiotic dosing regimens and the special patient populations which may beneﬁt most from these
approaches. The existing methods are based on monitoring of antibiotic concentrations and/or use of clinical covariates. Measured
concentrations can be correlated with predeﬁned pharmacokinetic/pharmacodynamic targets to guide clinicians in predicting the
necessary dose adjustment. Dosing nomograms are also available to relate observed concentrations or clinical covariates (e.g. creatinine
clearance) with optimal dosing. More precise dose prediction based on observed covariates is possible through the application of
population pharmacokinetic models. However, the most accurate estimation of individualized dosing requirements is achieved through
Bayesian forecasting which utilizes both measured concentration and clinical covariates. Various software programs are emerging to ease
clinical application. Whilst more studies are warranted to clarify the clinical outcomes associated with the different dose optimization
approaches, severely ill patients in the course of marked infections and/or inﬂammation including those with sepsis, septic shock, severe
trauma, burns injury, major surgery, febrile neutropenia, cystic ﬁbrosis, organ dysfunction and obesity are those groups which may
beneﬁt most from individualized dosing.
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E-mail: j.roberts2@uq.edu.auIntroductionThe widespread use of antibiotics has led to the emergence of
less susceptible, multidrug resistant, extensively drug resistant
and even pan–drug resistant organisms. With few advances inMicrobiol Infect 2015; 21: 886–893
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.002the development of new antibiotics since the 1970s, the clinical
reality of untreatable infections is becoming more common
[1,2]. Consequently, there has been a growing interest in the
redevelopment of old antibiotics. Given the emerging reports
of suboptimal antibiotic exposure from standard dosing regi-
mens in severely ill patient populations [3–6], a careful opti-
mization of dosing regimens will be crucial in order to avoid
underexposure and ensure successful reintroduction of old
antibiotics. Underexposure is driven by dynamic pathophysio-
logic changes in the pharmacokinetics (PK) and pharmacody-
namics (PD) of antibiotics; it is also due to the decreasing
susceptibility of organisms in clinical settings. To heighten theious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Sime et al. Optimization of dosing regimens 887clinical challenge, these PK changes are difﬁcult to predict
among patient groups, among patients in a group, and even on a
day-to-day basis in an individual patient [7].
Recent data suggest that current approaches to dosing are
not accounting for these dosing challenges [8]. Clinically, it is
difﬁcult to predict who needs different doses and to what
extent those doses should be modiﬁed. As a result, there has
been an increasing interest in the individualization of antibiotic
dosing, taking speciﬁc PK/PD changes into consideration [9].
This review summarizes the current approaches to optimiza-
tion of antibiotic dosing regimens and the special patient pop-
ulations most likely to beneﬁt from these approaches.Special patient populationsSome patient populations require special dosing considerations
as a result of an intense and complex pathophysiology. These
include critically ill patients with sepsis, septic shock, severe
trauma or burns injury, major surgery, febrile neutropenia,
cystic ﬁbrosis, organ dysfunction and obese patients [3–6].
Many of these patients have a state of systemic inﬂammation.
Particularly in patients with severe infections, trauma, burns,
pancreatitis, major surgery and ischemia, progression of severe
systemic inﬂammatory response syndrome (SIRS) is common.
During SIRS, various inﬂammatory mediators change patient
physiology, often manifesting as hyperdynamic effects on the
cardiovascular system as well as increased capillary permeability
[10,11]. SIRS can also lead to a spectrum of organ-system failure
which may necessitate extracorporeal membrane oxygenation
or renal replacement therapy [12]. Surgical drainage may play a
similar role of providing extra route of loss of inﬂammatory
ﬂuids and even antibiotics [13]. In addition, most of these pa-
tients have altered body water volumes associated with either
extensive ﬂuid resuscitation or altered cardiovascular and renalTABLE 1. Summary of pathophysiologic and other factors affecting
Description Type of antibiotic
Major distribution
site
Major elimination
pathway Fac
Hydrophilic β-Lactams (penicillins,
cephalosporins,
carbapenems)
Aminoglycosides
Glycopeptides
ECF Renal excretion Leak
H
F
V
P
A
M
Lipophilic Fluoroquinolones
Macrolides
Tetracyclines
Oxazolidinones
Streptogramins
Lincosamides
Metronidazole
ECF and intracellular Hepatic
metabolism
Gen
ECF, extracellular ﬂuid; Vd, volume of distribution; CL, clearance.
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antibiotics are associated with body water dynamics. Excess
water is shifted into the extracellular space, delivering more
molecules but ultimately diluting antibiotic concentration.
Further, increased ﬁltration of blood by kidneys, driven by
elevated cardiac output, can lead to a higher rate than normal of
elimination of solutes, including drugs like antibiotics [17].
Other patients have altered fat/muscle ratios as a result of
obesity, which may also profoundly inﬂuence drug distribution
properties [18].Role of pathophysiology in altered PKThe most important pathophysiologic changes necessitating
special antibiotic dosing considerations cause changes in the
volume of distribution and clearance of the drugs (Table 1) [19].
Changes in volume of distribution (Vd)
Increases in the Vd of hydrophilic antibiotics occur as a result of
SIRS-related expansion of the extracellular ﬂuid (ECF) volume.
Hypoalbuminemia is another factor that increases ECF volume
(and hence Vd) by reducing the plasma oncotic pressure.
Hypoalbuminemia also increases free concentration of drug in
plasma that can distribute into the ECF with the movement of
ﬂuid into that compartment. For instance, for ceftriaxone
(83–95% protein binding), the Vd can increase by up to 90% in
the critically ill [20]. Additional factors expanding Vd include
pathologic ﬂuid accumulations such as pleural effusions [21],
ascites [22] and mediastinitis [23]. Increases in Vd are associ-
ated with reduced plasma and tissue concentrations
[16,24–26]. This is particularly problematic for concentration-
dependent antibiotics as a result of the signiﬁcant reduction in
peak concentration that determines antibacterial activity for
this type of antibiotics.antibiotic pharmacokinetics
tors increasing Vd Factors increasing CL Factors decreasing CL
y capillaries
ypoalbuminemia
luid therapy
asoactive drugs
leural effusions
scites
ediastinitis
Augmented renal clearance
(high cardiac output, high
renal blood ﬂow, reduced
vascular resistance,
hypoalbuminemia, vasoactive
drugs, ﬂuid therapy)
Acute kidney injury
erally not affected Increased hepatic blood ﬂow
Enzyme induction (because of
drug interactions)
Hepatic impairment and
acute kidney injury
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In patients with acute leukaemia and in the critically ill with
sepsis, trauma, burn injury and major surgery, the hyper-
dynamic state described above is associated with an elevated
cardiac output which causes increased renal blood ﬂow and
subsequently increased glomerular ﬁltration [27–29]. Other
factors such as aggressive ﬂuid therapy and the use of vasoactive
drugs may also contribute to increases in renal blood ﬂow and
glomerular ﬁltration rate. Similar effects probably also occur in
patients with cystic ﬁbrosis and obesity. In addition to these
effects, hypoalbuminemia increases proportions of the unbound
drug available for ﬁltration. Ultimately, there is enhanced renal
clearance of renally cleared antibiotics, a phenomenon referred
to as augmented renal clearance (ARC) [17]. ARC is deﬁned as
creatinine clearance >130 mL/min/1.73 m2 [28]. The prevalence
is appreciably high in the critically ill population (>50%) and is
probably most common in those patients with traumatic injury
(about 85%) [27,30]. Increased elimination through ARC has a
particularly marked inﬂuence on time-dependent antibiotics,
which require maintenance of optimal concentrations for a
prolonged time within a dosing interval.
Acute kidney injury (AKI)
The inﬂuence of AKI on dosing requirements is complex. With
severe renal impairment, cefepime, for instance, can accumulate
to an extent such that without dose reduction, neurotoxicity
including seizures will occur [31–33]. For some antibiotics such
as ﬂucloxacillin and ciproﬂoxacin, which are subject to both
renal and nonrenal clearance, AKI may not result in accumu-
lation as a result of up-regulation of alternative clearance
mechanisms. Thus, overzealous dose reduction based on renal
function may result in subtherapeutic concentrations in some
cases. However, when multiple organ derangements occurClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectimpairing the alternative routes of elimination, very high anti-
biotic concentrations may result with unadjusted doses
[34–37]. When accumulation occurs, the dilutional effect of
concurrent Vd expansion may be profound such that concen-
trations may still be subtherapeutic, although this effect is only
likely in the ﬁrst 24 to 48 hours of therapy (Fig. 1). Another
complication of AKI is tubular dysfunction involving both
secretion and reabsorption. While these effects may decrease
the clearance of antibiotics such as β-lactams which may partly
undergo tubular secretion, dysfunction of these processes may
augment clearance of other drugs such as ﬂuconazole which
undergo substantial reabsorption. Consequently, higher ﬂu-
conazole dosing may be required in patients with AKI [38,39].
An additional complicating factor in AKI is variable clearance
from extracorporeal therapies such as renal replacement
therapy. Dosing during renal replacement therapy is not an easy
task; numerous factors should be considered, as has been
reviewed in detail elsewhere [39–42].Altered PK/PD in special populationsIn addition to PK-related changes, emerging studies indicate that
the conventional targets aimed while treating non–critically ill
patients may not be adequate in the critically ill. Under condi-
tion of severe illness, increased exposure may be necessary to
achieve desirable clinical outcomes. For example, even though
non–critically ill patients may only require minimal β-lactam
antibiotic exposures of 40% to 70% fT>MIC, recent clinical
studies suggest 100% fT>MIC may be a minimum target required
to ensure optimal outcomes in the critically ill [43].
The status of host immunity may also profoundly inﬂuence
the magnitude of PK/PD target that predicts optimal outcome.FIG. 1. Schematic illustrating effects of
altered volume of distribution and clear-
ance on plasma concentration of hydro-
philic antibiotics.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 886–893
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ceftazidime that was required to prevent mortality was 70
times greater in leukopenic rats compared to normal rats.
Other animal studies have also shown that high exposure
(90–100% fT>MIC) is necessary in the setting of profound
neutropenia [45]. Data from clinical studies support increased
fT>MIC for optimal response [46]. However, standard doses of
many β-lactams frequently fail to attain even the traditional PK/
PD targets [8,25]. Such underexposure is a high risk for the
emergence of bacteria with reduced susceptibility [47].Altered bacterial susceptibilityThe pattern of bacterial susceptibility in special patient pop-
ulations is another emerging concern. There is a general indi-
cation that decreased susceptibility of organisms is likely in the
critically ill, ultimately necessitating increased dosing [48,49].
Decreased susceptibility may be encountered at the
commencement of therapy or may emerge during therapy. If
the speciﬁc minimum inhibitory concentration (MIC) is deter-
mined, PK/PD-based dosing can make due considerations for
any altered susceptibility by ensuring the PK numerator sufﬁ-
ciently corresponds to the MIC denominator such that the PK/
PD target is still achieved. However, empiric dosing rarely ac-
counts for this, risking selection of resistant organisms. For
treatment that aims to suppress the emergence of resistant
organisms, dosing that targets the mutant prevention concen-
tration (MPC) rather than the MIC has been suggested [50,51].
However, the high dose required to achieve MPC targets
inevitably risks toxicity, suggesting that this approach may notFIG. 2. Examples of PK/PD-based dose optimization approaches. PK, pharm
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologybe possible in all cases [52]. To our knowledge, there is no
clinical study that has utilized MPC as a target for a dosing
threshold. Hence, with the scarce data available, it may be
premature to reﬂect on the pros and cons.Approaches for antibiotic dose optimizationThe unpredictability as well as the within- and between-patient
PK/PD variability has led to a renewed effort to individualize
antibiotic dosing. Real-time therapeutic drug monitoring
(TDM)-guided dose optimization in combination with the use of
PK/PD models, dosing simulation software and dosing nomo-
grams is an evolving practice (Fig. 2).
Therapeutic drug monitoring
The scope of antibiotic TDM has expanded from the antibiotics
monitored traditionally for toxicity, aminoglycosides and gly-
copeptides, to include other classes of antibiotics which aim to
maximize therapeutic efﬁcacy: β-lactams, quinolones, linezolid
and colistin [9]. Generally, the common practice of TDM-
guided dose optimization involves measuring plasma antibiotic
concentrations at a speciﬁc time in a dosing interval, depending
on the PK/PD properties of the antibiotic, and subsequently
adjusting the dosing in reference to a nomogram. Amino-
glycoside TDM is more established than other antibiotics, with
a reasonable level of evidence supporting outcome beneﬁts
[53]. For vancomycin, the collective literature suggests TDM-
guided dose optimization is associated with improved clinical
outcomes [54]. Routine β-lactam antibiotic TDM is currently
limited to a few institutions [55]. Among the quinolones,acokinetic; PD, pharmacodynamic.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 886–893
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Linezolid is another antibiotic sparingly subject to TDM for
dose optimization [57].
Pharmacometric approaches
The wider TDM practice considers measured concentrations
to predict the optimal dose without taking into account an
individual’s speciﬁc covariate characteristics that may affect PK.
Consequently, while adjusted dosing regimens improve the
probability of attaining PK/PD targets, it is not uncommon to
see persisting suboptimal exposure even after initial dose
adjustment [58]. When multiple concentrations are monitored,
a simple log-linear regression analysis may help gross estimation
of PK parameters, which can better guide dosing. However,
more precise dose prediction depends on understanding of PK
variability and our ability to quantify this variability in relation to
easily measurable clinical covariates. This is possible through
the application of population PK models.
Population PK models describe the relationship between
dose, plasma concentration and clinical covariates in a particular
patient population. Such mathematical models can utilize prior
PK information from the model to estimate patient speciﬁc PK
parameters based on the available clinical covariates. A precise
dose prediction for the individual patient can then be made by
using these speciﬁc PK parameter estimates [59].
While the use of PK models may be more precise than the
simplistic approach of using clinical judgement, it is not without
limitations. One pitfall of clinical judgement is that estimation of
dosing does not interpret actual concentrations from the
particular patient but only observed clinical covariates. By
inputting information from a TDM concentration explaining
how the drug is behaving in a particular patient and combining it
with prior information in a PK model data explaining the drug’s
behaviour in a similar patient population, an individualized
patient-speciﬁc model can be developed to enable accurate
dose prediction. This is possible through the Bayesian approach
of estimation. Feedback from TDM allows reﬁnement of PK
parameter estimation to enable the model best describe both
the patient and the population data. It also allows progressive
updating of the parameters by integrating further TDM con-
centration from subsequent patients. Parameter estimates ob-
tained after such adjustment enable more accurate prediction
of dosing for a particular patient. Clinical studies have demon-
strated excellent predictive performance of the Bayesian
method [60].
The precision of Bayesian estimation is dependent on the
quality of the prior model selected [61]. The model should be
able to accurately represent the relevant special population.
Gross assumption of similarity between populations may give
rise to less precise prediction. For example, application ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmodels developed in the critically ill for neutropenic cancer
patients resulted only in good to fair precision [62]. Even after
selecting the most relevant population model, predictive per-
formance of different models available may be somehow vari-
able [63]. Therefore, clinical validation of these methods is
important.
Nomograms are generally based on simpler PK analysis,
often in non–critically ill subjects, and thus may have poor
predictive performance. Computer software can perform
advanced PK analysis and hence are more accurate. Reviews of
the available computer tools have recently been published by
Fuchs et al. [64] and Roberts and Lipman [9]. While the de-
velopments are promising, such applications have yet to
improve in their scope and versatility.Lessons from existing antibioticsOlder antibiotics have not been subjected to advanced modern
PK/PD-based dose optimization techniques, and much knowl-
edge can be gained from this [65]. Firstly, exposure–effect
relationships for old drugs need to be thoroughly deﬁned.
Advanced PD modelling techniques are now available to accu-
rately describe the concentration–effect relationship and an
optimal PK/PD target [66–68]. This will enable us to choose a
Cmax/MIC, fT>MIC or area under the curve/MIC target for
effective dosing regimens. Secondly, PK properties have to be
examined in the different patient populations the antibiotic is
likely to be used. Population PK models can be combined with
clinical trial simulation to help in the selection of new dosing
regimens. Finally, rational design of comparative outcome trials
should incorporate PK/PD considerations, including conﬁrma-
tion of the relationship between clinical outcome and the PK/
PD end points predicted from the preclinical studies.
The ongoing, apparently successful effort to reintroduce
colistin best exempliﬁes the beneﬁt of PK/PD approach in the
revival of a forgotten antibiotic [69]. Its exposure–effect re-
lationships have been recently described [70,71], and recent PK
studies are revealing altered PK and suboptimal dosing in the
critically ill [72,73]. Consequently, based on a population PK
analysis, novel dosing approaches are emerging [74–76]. Some
have even described TDM practice [77,78]. Thus, a clearer
picture on how to dose colistin is emerging. Similar approaches
would be instrumental for other older antibiotics of interest,
including fosfomycin [79], temocillin [80], fusidic acid [81] and
nitrofurantoin [82]. Some have physicochemical and PK prop-
erties that may lead to a different dose–exposure relationship
in special populations [83,84]. Dose optimization of temocillin
can be based on our knowledge of how to optimize β-lactams.
A practical challenge would be the high and variable proteinious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 886–893
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presented at 18th European Congress of Clinical Microbiology
and Infectious Diseases (ECCMID), abstract O146 2008). High
protein binding is also a challenge posed by fusidic acid in
addition to its complex nonlinear PK, which demands a novel
dosing strategy [85,86]. All in all, while there is some progress
on few old antibiotics, the lack of previous data for others like
nitrofurantoin warrants fresh PK/PD studies.ConclusionThere is compelling evidence that conventional dosing regimens
of several antibiotics result in variable and frequently low
concentrations in special populations. A clear concentration–
effect relationship also exists for antibiotics and bacterial killing
and emergence of resistance. There being no end-of-needle
effect for measuring antibiotic effectiveness, PK/PD parame-
ters that characterize the relationship between antibacterial
activity and measured concentrations are valuable tools avail-
able to gauge the adequacy of dosing. PK/PD knowledge can
assist rational and robust dose optimization as well as permit
individualized therapy in special patient populations. Through
the application of such knowledge, a promising prospect is
emerging in the revival of old antibiotics.Transparency declarationAll authors report no conﬂicts of interest relevant to this
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